Early Accrual of Organ Damage in Systemic Sclerosis: Rationale for Development of a Disease Damage Index

Valentini G Iudici M Walker UA et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis 2017;76 (1):270–276

Minier T Nagy Z Bálint Z et al. Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology (Oxford) 2010;49 (6):1133–1145

Tay T Ferdowsi N Baron M et al. Damage Index Working Group of the Scleroderma Clinical Trials Consortium. Measures of disease status in systemic sclerosis: A systematic review. Semin Arthritis Rheum 2017;46 (4):473–487

Melsens K De Keyser F Decuman S Piette Y Vandecasteele E Smith V Disease activity indices in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol 2016;34Suppl 100 (5):186–192

Khanna D Berrocal VJ Giannini EH et al. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheum (Munch) 2016;68 (2):299–311

Distler O Behrens F Pittrow D et al. EPOSS-Omeract Group. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum 2008;59 (6):867–875

Medsger TA Jr Silman AJ Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26 (10):2159–2167

Geirsson AJ Wollheim FA Akesson A Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001;60 (12):1117–1122

Morita Y Muro Y Sugiura K Tomita Y Tamakoshi K Results of the Health Assessment Questionnaire for Japanese patients with systemic sclerosis measuring functional impairment in systemic sclerosis versus other connective tissue diseases. Clin Exp Rheumatol 2007;25 (3):367–372

Furst DE Clements PJ Hillis S et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989;32 (5):584–593

Casas JA Subauste CP Alarcón GS A new promising treatment in systemic sclerosis: 5-fluorouracil. Ann Rheum Dis 1987;46 (10):763–767

Hughes P Holt S Rowell NR Dodd J Thymus-dependent (T) lymphocyte deficiency in progressive systemic sclerosis. Br J Dermatol 1976;95 (5):469–473

Avouac J Walker U Tyndall A Kahan A Matucci-Cerinic M Allanore Y EUSTAR. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010;37 (7):1488–1501

Allanore Y Denton CP Krieg T et al. DUO Investigators. Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. Ann Rheum Dis 2016;75 (9):1736–1740

Nihtyanova SI Brough GM Black CM Denton CP Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008;67 (1):120–123

Caramaschi P Dalla Gassa A Prati D et al. Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost. Rheumatol Int 2012;32 (7):1933–1938

Morrisroe KB Nikpour M Proudman SM Musculoskeletal Manifestations of Systemic Sclerosis. Rheum Dis Clin North Am 2015;41 (3):507–518

Bassel M Hudson M Taillefer SS Schieir O Baron M Thombs BD Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 2011;50 (4):762–767

Steen VD Conte C Owens GR Medsger TA Jr Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37 (9):1283–1289

Khanna D Tseng CH Farmani N et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011;63 (10):3078–3085

Nikpour M Baron M Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 2014;26 (2):131–137

McLaughlin VV Archer SL Badesch DB et al. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119 (16):2250–2294

van den Hoogen F Khanna D Fransen J et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72 (11):1747–1755

Galiè N Humbert M Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37 (1):67–119

Meier FM Frommer KW Dinser R et al. EUSTAR Co-authors. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71 (8):1355–1360

Follansbee WP Zerbe TR Medsger TA Jr Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993;125 (1):194–203

Ranque B Authier FJ Le-Guern V et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009;68 (9):1474–1477

Paik JJ Wigley FM Lloyd TE et al. Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness. Arthritis Care Res (Hoboken) 2015;67 (10):1416–1425

Sjogren RW Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996;8 (6):569–575

Gyger G Baron M Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 2012;14 (1):22–29

Kostis JB Seibold JR Turkevich D et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988;84 (6):1007–1015

Ferri C Bernini L Bongiorni MG et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum 1985;28 (11):1259–1266

Denton CP Black CM Scleroderma clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18 (3):271–290

Ferdowsi N Burchell JL Mancuso S et al. Development of a disease damage index in systemic sclerosis using consensus and data-driven methods. Abstracts from the 4^th Systemic Sclerosis World Congress, Feb 2016, Lisbon, Portugal. J Scleroderma Relat Disord 2016;1 (1):39

Medsger TA Jr Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003 29 (2):255–273 vi.